Resources

Canadian Public Reimbursement Timelines

Improving access to new medicines is a critical challenge within Canada’s healthcare system – and one of Innovative Medicines Canada’s key focus areas.

We believe that transparent information-sharing is essential to collaboratively identifying solutions and strengthening the sustainability of Canadian health systems. To support this effort, Innovative Medicines Canada has created this resource hub to provide updates and trends related to drug reimbursement timelines in Canada and OECD countries.

This page is regularly updated with data and analysis on public reimbursement processes, including:

Time to access new medicines
Volume of negotiations underway
Key pCPA performance metrics

The data is independently collected and aggregated by IMC, using sources such as IQVIA International Reimbursement Comparison, Health Canada, Canada’s Drug Agency (CDA), Institut national d’excellence en santé et services sociaux (INESSS), pan-Canadian Pharmaceutical Alliance (pCPA), and various Canadian provincial formularies.

CANADIAN PUBLIC REIMBURSEMENT TIMELINES RESOURCES

November 07, 2022

Public Reimbursement Timelines: a Pandemic Snapshot

Learn more | View

pCPA timeline data

Access downloadable trend charts reflecting the most recent quarterly data:

Download All

Additional pCPA resources

Access to Medicine • November 17, 2022

Innovative Agreements Framework

Many products coming to market are poorly served by traditional negotiation approaches. This document describes innovative agreements being used in jurisdictions outside Canada. We prepared it to guide discussions with the pCPA Governing Council on the merits of jointly developing an innovative agreements framework.

Learn more | View